Company intelligence / Profile preview

NUCo-Development

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Other

Overview

NUCo-Development is a Swiss-based biotechnology company focused on the development of next-generation metabolic therapies. The company specializes in the design of oral small molecule agonists targeting the GLP-1, GIP, and glucagon receptors to treat obesity and type 2 diabetes. By leveraging its expertise in peptide-to-small-molecule conversion, NUCo-Development aims to provide more accessible and convenient alternatives to current injectable incretin therapies. The company's lead programs are currently in the pre-clinical stage, with a focus on optimizing potency and oral bioavailability.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on NUCo-Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUCo-Development.

Explore the full profile